Navigation Links
Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations
Date:12/15/2009

ntitative RT-PCR by Oncotype DX, to explore the association between polysomy 17 (extra copies of chromosome 17, a condition found in breast cancer patients that can complicate the interpretation of HER2 testing results), HER2 status and breast cancer death. Polysomy 17 was found in HER2-amplified tumors in approximately a third of cases. While differences were not statistically significant, HER2-positive patients with polysomy 17 tended to have a worse prognosis than other breast cancer patients. Quantitative RT-PCR by Oncotype DX for HER2 status is highly concordant with HER2 status assessed by FISH and therefore is an alternative to FISH.

About Oncotype DX®

The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer test has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. As of November 2009, more than 8,000 physicians have ordered more than 120,000 tests in over 50 countries, and both Medicare and private health plans covering over 90 percent of U.S. insured lives, provide reimbursement for Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-nega
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
2. New Genomic Test for Coronary Artery Disease Now Available at The Heart & Vascular Center of Arizona
3. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
4. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
5. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
6. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
7. Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development
8. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
9. Curemark CEO Presents at Epigenomics Conference
10. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
11. Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
(Date:1/22/2015)... WOODBRIDGE, ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for cardiovascular disease ... summary of the Company,s accomplishments in 2014 and its outlook ... Dear Fellow Shareholders, We would like ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... in Carotid Atherosclerosis, LEXINGTON, Mass., Oct. 24 ... its pivotal clinical trial (PROVIDENCE-1),studying the effect of ... peripheral arterial disease (PAD) will be,presented on November ... late breaker,Scientific Session at the American Heart Association,s ...
... Today the National Legal and Policy,Center (NLPC) asked ... for,International Development (USAID) to investigate the possibility that ... groups operating,needle exchange programs for drug users in ... activist George,Soros are recipients of these legally questionable ...
Cached Medicine Technology:ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 2ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 3Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups 2
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the ... created for kids with cancer. The Chemo Duck App, available on ... with enjoyable games to help children of all ages living with ... to keep kids entertained, educated and at ease while waiting for ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... ... be covered by medical insurance will be provided by Khanna institute in Beverly Hills ... (Vocus) April 13, 2010 -- ... for eye and sight problems, hereby announces that it is offering its Beverly Hills patients ...
... contaminated water, and their health effects, will be the ... Superfund Research Program during the next five years. The ... that the Superfund Research Program, funded since 1989, will ... 2015 to conduct the research. Four environmental projects ...
... A research project of the Neuroscience Center of the ... sustaining memory traces of visual stimuli in the human ... memory is associated with synchronisation of neurons, which facilitates ... basis of interaction between the brain areas, it was ...
... ... that 80% of Women Enjoy Reading or Viewing Pornography; 73% Wish They Were Having More Sex. ... San Francisco, CA (PRWEB) April 13, ... had a copy of What Women Really Want in Bed: The Surprising Secrets Women Wish ...
... lowered stroke risk, but only if they didn,t smoke, study ... indulge in moderate drinking, you,ve probably heard that it might ... new British study supports that notion, but it also finds ... apply to smokers. , "Any potential beneficial effect of drinking ...
... Autism in ... concern with no known cure. The causes of autism are hotly debated, but a new ... ... of children who have received this stem cell treatment for autism , a group of ...
Cached Medicine News:Health News:Khanna Institute to Provide Intacs Corneal Implants in Beverly Hills 2Health News:Khanna Institute to Provide Intacs Corneal Implants in Beverly Hills 3Health News:University of Arizona Superfund Research Program receives $14 million 2Health News:Human working memory is based on dynamic interaction networks in the brain 2Health News:'What Women Really Want In Bed' Is A Man's Guide To Giving Her The Sex She Wants 2Health News:'What Women Really Want In Bed' Is A Man's Guide To Giving Her The Sex She Wants 3Health News:'What Women Really Want In Bed' Is A Man's Guide To Giving Her The Sex She Wants 4Health News:Smoking May Erase Heart Benefits of Light Drinking 2Health News:Smoking May Erase Heart Benefits of Light Drinking 3Health News:Thanks to a New Stem Cell Therapy, a 9-year Old Autistic Boy Talks to his Father for the First Time 2Health News:Thanks to a New Stem Cell Therapy, a 9-year Old Autistic Boy Talks to his Father for the First Time 3Health News:Thanks to a New Stem Cell Therapy, a 9-year Old Autistic Boy Talks to his Father for the First Time 4
... TME 227 T is a ... temporary cardiac pacing and monitoring ... The TME 227 T features ... myocardium, which allows safe and ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: